Polar Capital LLP acquired a new stake in Immunomedics, Inc. (NASDAQ:IMMU) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 904,416 shares of the biopharmaceutical company’s stock, valued at approximately $12,906,000. Polar Capital LLP owned about 0.47% of Immunomedics as of its most recent SEC filing.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Exane Derivatives acquired a new stake in shares of Immunomedics in the fourth quarter valued at approximately $32,000. Karp Capital Management Corp bought a new position in shares of Immunomedics in the fourth quarter valued at $33,000. North Star Investment Management Corp. bought a new position in shares of Immunomedics in the fourth quarter valued at $50,000. Pearl River Capital LLC bought a new position in shares of Immunomedics in the fourth quarter valued at $66,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Immunomedics by 16.3% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,151 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 1,140 shares in the last quarter. Institutional investors own 84.64% of the company’s stock.
IMMU stock opened at $17.94 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 13.45 and a quick ratio of 13.45. Immunomedics, Inc. has a one year low of $11.55 and a one year high of $27.33. The firm has a market cap of $3.42 billion, a price-to-earnings ratio of -17.42 and a beta of 2.08.
Immunomedics, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively.
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.